# Anifrolumab Treatment for 24 Weeks in Patients With Primary Sjögren's Syndrome

> **NCT05383677** · PHASE2 · UNKNOWN · sponsor: **University Medical Center Groningen** · enrollment: 30 (estimated)

## Conditions studied

- Sjogren's Syndrome

## Interventions

- **DRUG:** Anifrolumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05383677
- **Lead sponsor:** University Medical Center Groningen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-01
- **Primary completion:** 2024-05-01
- **Final completion:** 2024-08-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-12-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05383677

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05383677, "Anifrolumab Treatment for 24 Weeks in Patients With Primary Sjögren's Syndrome". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05383677. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*